Skip to main content

Table 1 Clinical characteristics according to VFA levels

From: Is visceral adiposity a modifier for the impact of blood pressure on arterial stiffness and albuminuria in patients with type 2 diabetes?

 

VFA < 100 cm2 (N = 341)

VFA ≥ 100 cm2 (N = 297)

p values

Age (years)

66 ± 12

62 ± 13

<0.001

Gender (% male)

57

63

0.196

SBP (mmHg)

128 ± 20

132 ± 17

0.016

DBP (mmHg)

73 ± 12

78 ± 12

<0.001

HbA1c (mmol/mol)

71.6 ± 20.2

75.0 ± 19.5

0.029

HbA1c (%)

8.7 ± 1.8

9.0 ± 1.8

 

HDL-cholesterol (mmol/l)

1.32 ± 0.42

1.19 ± 0.31

<0.001

LDL-cholesterol (mmol/l)

2.87 (2.29–3.56)

2.79 (2.26–3.44)

0.515

Triglycerides (mmol/l)

1.31 (0.98–1.86)

1.61 (1.19–2.26)

<0.001

Urinary C-peptide (μg/day)

42 (27–67)

60 (35–99)

<0.001

Duration of diabetes (years)

12 (5–20)

10 (4–16)

0.044

Current smoker (%)

22

25

0.452

History of CVD

13

17

0.183

UAE (mg/day)

11 (7–26)

19 (10–58)

0.001

eGFR (ml/min/1.73 m2)

72.0 ± 23.3

71.5 ± 25.6

0.791

AST (U/l)

22 (17–28)

24 (19–41)

<0.001

ALT (U/l)

19 (14–30)

28 (18–48)

<0.001

C-reactive protein (mg/l)

0.80 (0.40–1.95)

1.60 (0.80–3.60)

<0.001

PDR (%)

19

12

0.536

CV-RR (%)

3.3 (2.2–4.8)

3.6 (2.3–5.3)

0.109

ba-PWV (cm/s)

1711 (1459–1906)

1582 (1411–1785)

0.007

Body mass index (kg/m2)

23.5 ± 3.2

29.4 ± 4.4

<0.001

Waist circumference (cm)

86 ± 9

102 ± 11

<0.001

Visceral fat area (cm2)

74 (57–87)

133 (114–152)

<0.001

Subcutaneous fat area (cm2)

144 (120–178)

236 (194–284)

<0.001

Insulin (%)

75

61

0.002

CCBs (%)

29

39

0.023

ARBs (%)

35

53

<0.001

Statin (%)

42

52

0.050

Anti-platelets (%)

17

22

0.322

  1. ALT alanine aminotransferase, ARB angiotensin receptor blocker, AST asparatate aminotransferase, baPWV brachial-ankle pulse wave velocity, CCB calcium channel blocker, CVD cardiovascular disease, CV-RR coefficient of variation of R–R intervals, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, PDR proliferative diabetic retinopathy, SBP systolic blood pressure